Vizora日本語

Shin Nippon Biomedical LaboratoriesSHIN NIPPON BIOMEDICAL LABORATORIES, LTD.2395東証プライムサービス業FY ending Mar 2026, consolidated, J-GAAP

Shin Nippon Biomedical Laboratories FY ending Mar 2025 results

About 97% of Shin Nippon Biomedical Laboratories's sales come from CRO Services, with Medipolis and Other making up much of the rest.

Out of every ¥100 of sales, about ¥9 is left as operating profit.

Revenue changed +22.5% from the prior year, operating profit -28.3%.

Revenue and profit pattern

Revenue up, profit downRevenue grew faster

Revenue +22.5% · profit -28.3%, calculated from disclosed figures.

Operating leverage: -1.25× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2024 → FY ending Mar 2025

Revenue
+22.5%¥26.5B → ¥32.4B
Gross profit
+18.8%¥14.3B → ¥17B
Operating income
-28.3%¥4.16B → ¥2.99B
Net income attributable to owners
-11.0%¥5.53B → ¥4.92B
Operating cash flow
+233.9%¥2.11B → ¥7.04B
Free cash flow
Loss-¥6.5B → -¥3.9B

Where the money goes

FY ending Mar 2024 → FY ending Mar 2025

Where ¥100 of sales goes

For every ¥100 Shin Nippon Biomedical Laboratories sells, how much goes where, and how much is kept.

FY ending Mar 2025
Cost of sales
¥48
SG&A
¥43
Operating profit
¥9
Net profit kept
¥15

Annual margin trends

Gross margin52.3%
FY ending Mar 2020: 52.3%52.3%FY ending Mar 2021: 50.0%50.0%FY ending Mar 2022: 54.6%54.6%FY ending Mar 2023: 52.0%52.0%FY ending Mar 2024: 54.0%54.0%FY ending Mar 2025: 52.3%52.3%FY20FY21FY22FY23FY24FY25
Operating margin9.2%
FY ending Mar 2020: 15.3%15.3%FY ending Mar 2021: 16.7%16.7%FY ending Mar 2022: 23.6%23.6%FY ending Mar 2023: 20.9%20.9%FY ending Mar 2024: 15.7%15.7%FY ending Mar 2025: 9.2%9.2%FY20FY21FY22FY23FY24FY25
Net margin15.2%
FY ending Mar 2020: 17.5%17.5%FY ending Mar 2021: 24.2%24.2%FY ending Mar 2022: 40.2%40.2%FY ending Mar 2023: 24.2%24.2%FY ending Mar 2024: 20.9%20.9%FY ending Mar 2025: 15.2%15.2%FY20FY21FY22FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2025

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第53期(2025/04/01－2026/03/31)

    ID S100YK732026-06-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第52期(2024/04/01－2025/03/31)

    ID S100W81X2025-06-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第51期(2023/04/01－2024/03/31)

    ID S100TS9X2024-06-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第50期(2022/04/01－2023/03/31)

    ID S100R8752023-06-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第49期(令和3年4月1日－令和4年3月31日)

    ID S100OK5K2022-06-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第48期(令和2年4月1日－令和3年3月31日)

    ID S100LVCO2021-06-30Open

Extracted from XBRL: 55 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image